Efficacy and safety of biosimilar infliximab CT-P13 in the treatment of psoriasis and psoriatic arthritis: 1-year follow-up

Kurizky, Patrícia Shu; Galvão, Leticia Oba; Martins, Gisele

doi:10.1590/abd1806-4841.20198358

Cited by 4 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…92 European studies on psoriasis and psoriatic arthritis highlight the positive response for CT-P13 with patient stability. 93 According to the members of an international psoriasis council, biosimilars should be produced with ap-proval and in a standardized, high-quality manner. 94 In 2016, a study was conducted by Dapavo and colleagues 95 by dividing patients suffering from plaque psoriasis into two groups.…”

Section: Prospective Role Of Ct-p13 In Psoriatic Arthritismentioning

confidence: 99%

Clinical Benefits of Switching from Original Infliximab to its Biosimilar (CT-P13) as a Potential TNF-α Inhibitor

Kumari¹,

Prasad²,

Kumar³

et al. 2020

Journal of Exploratory Research in Pharmacology

View full text Add to dashboard Cite

Tumor necrosis factor-alpha (TNF-α) is implicated in the process of various autoimmune and inflammatory diseases through binding to its receptor, the tumor necrosis factor receptor. Nowadays, monoclonal anti-TNF-α antibody is used for the treatment of these diseases because it can neutralize TNF-α to block the relevant signaling responsible for the pathogenesis of these diseases. Currently, such antibody-based therapies have been demonstrated to be effective in controlling rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease and ulcerative colitis. Infliximab is the first monoclonal antibody for the treatment of rheumatoid arthritis and has been approved for the intervention of other autoimmune and inflammatory diseases in the clinic. Although infliximab is considered highly efficacious, more so than common medications such as methotrexate and calcipotriol, its potential disadvantages, including loss of response in some patients, drug-related adverse events and particularly high cost, have motivated chemists and researchers to shift towards its biosimilar, CT-P13. CT-P13 has a better tolerance and much less cost, attracting more attention. Here, we summarize the clinical findings of CT-P13 from clinical trials in various diseases.

show abstract

Section: Prospective Role Of Ct-p13 In Psoriatic Arthritismentioning

confidence: 99%

Clinical Benefits of Switching from Original Infliximab to its Biosimilar (CT-P13) as a Potential TNF-α Inhibitor

Kumari¹,

Prasad²,

Kumar³

et al. 2020

Journal of Exploratory Research in Pharmacology

View full text Add to dashboard Cite

show abstract

“…The central role of TNF-a in inflammation has been demonstrated by the ability of agents that block the action of TNF-a to treat a range of inflammatory conditions, including rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease and psoriasis. [13][14][15] The effects of TNF-a on lipid and glucose metabolism suggest that TNF-a inhibitors, currently used in the treatment of several inflammatory diseases, may have a role in the reduction in plasma glucose, and in ameliorating lipid profile. Moreover, a lower prevalence of metabolic syndrome has been seen in patients treated with anti-TNF-a agents.…”

Section: Introductionmentioning

confidence: 99%

Effects of TNF-α antagonist infliximab on fructose-induced metabolic syndrome in rats

et al. 2020

View full text Add to dashboard Cite

Public health issues have been raised regarding fructose toxicity and its serious metabolic disorders. Deleterious effects of high fructose intake on insulin sensitivity, body weight, lipid homeostasis have been identified. The new millennium has witnessed the emergence of a modern epidemic, the metabolic syndrome (MS), in approximately 25% of the world’s adult population. The current study aimed to investigate the effect of the TNF-α antagonist infliximab on fructose-induced MS in rats. Rats were administered fructose (10%) in drinking water for 12 weeks to induce the experimental MS model. infliximab (5 mg/kg) was injected once weekly intraperitoneally starting on the 13th week for 4 weeks. Increase in body weight, blood glucose level, serum triglycerides (TGs), adiponectin level and blood pressure were present in MS rats. They also prompted increases in serum of leptin, TNF-α, and malondialdehyde (MDA) levels. Treatment with infliximab did not affect body weight, hyperglycemia or hypertension, but decreased serum TGs and increased serum HDL-c levels. Infliximab also decreased adiponectin levels. Surprisingly, infliximab increased MDA above its value in the MS group. These results reflect the fact that infliximab affects the manifestations of MS in rats. Though infliximab reduced TGs, increased HDL-c levels, reversed adiponectin resistance occurred by fructose, the drug failed to combat MS-mediated hyperglycemia, hypertension, and elevated MDA above the insult.

show abstract

Infliximab

2021

Reactions Weekly

View full text Add to dashboard Cite

Efficacy and safety of biosimilar infliximab CT-P13 in the treatment of psoriasis and psoriatic arthritis: 1-year follow-up

Cited by 4 publications

References 7 publications

Clinical Benefits of Switching from Original Infliximab to its Biosimilar (CT-P13) as a Potential TNF-α Inhibitor

Clinical Benefits of Switching from Original Infliximab to its Biosimilar (CT-P13) as a Potential TNF-α Inhibitor

Effects of TNF-α antagonist infliximab on fructose-induced metabolic syndrome in rats

Infliximab

Contact Info

Product

Resources

About